PATENT CLAIM ANALYSIS

Application Number: 15971970
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.

Claim (Index 42):
The method of  claim 34 , wherein administration of the antisense oligonucleotide conjugate reduces the level of serum LDL cholesterol.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 93.0
- Lexical Diversity: 1.29268
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14897223', '15836144', '15971951', '14443367', '13139696']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8649954218279075
- 35 USC 102 Novelty (BERT): 0.6110694919939672
- Combined Prediction Score: 0.8396028288445134
- Mean Citation Score: 627.411042
- Max Citation Score: 759.758
- Similarity Product: 470.12814001107216

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test